Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual list ... as number 1,361 in growth for the three years through 2014. Being named to ... privately held organizations in the country. , “We are thrilled to make the ...
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... PLYMOUTH, Mich., Nov. 13 Esperion Therapeutics, a ... and commercialize treatments for cardiovascular and metabolic diseases, ... Phase I clinical study for ETC-1002, the company,s ... the levels of plasma lipids and lipoproteins. The ...
... Nov. 13 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, Inc. (OTC Bulletin ... leading plasma-based pharmaceutical companies in China, today,announced that the ... ET on,Monday, November 16, 2009, to discuss the 2009 ... Hosting the call will be ...
... ... Chief Discusses DuPont Innovations that Address Energy Opportunities , ... Nashville, Tenn. (Vocus) November 13, 2009 -- DuPont ... Institute of Chemical Engineers (AIChE) for its role in delivering innovation that has ...
Cached Biology Technology:Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002 2China Biologic Schedules Conference Call to Discuss Third Quarter 2009 Financial Results 2DuPont Receives Corporate Innovation Award 2DuPont Receives Corporate Innovation Award 3DuPont Receives Corporate Innovation Award 4
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... journal Proceedings of the National Academy of Sciences , ... key player in regulating chromatin in yeast and humans. ... and a scientist at The Centre for Molecular Medicine and ... a dynamic DNA-protein complex, is involved in numerous cellular processes ...
... Ground-breaking discoveries by Michigan State University researchers could ... commercial colonies. The MSU researchers for the first ... that help channel sodium ions through cell membranes of ... frog eggs, also found that these proteins react to ...
... The castration of pigs prevents the "boar taint" smell in ... However in practice this can be very different. Now, for ... the conditions of castration on European pigs. The main conclusion ... is that these animals are castrated directly by the livestock ...
Cached Biology News:MSU research may lead to new ways to control honeybee parasite 277 percent of European pigs are castrated without anesthetic 2
... rat tissue extracts (liver, kidney, spleen, and heart) ... extract. It was also tested with microsomal fractions ... A simple and reliable method for measuring NDPase ... of the inorganic phosphate released from NDP by ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... through 63 ligand binding ... a broad therapeutic range. ... many non human tissue ... assays. Used to ...
... Receptor (PR) Competitor Assay Kits are ... progesterone receptor binding compounds using fluorescence ... a fusion of glutathione transferase to ... progesterone receptor [PR-LBD(GST)] and a proprietary, ...
Biology Products: